Image courtesy of Mala Ananth
Researchers have identified a positron emission tomography imaging agent that could identify the patients that are more likely to benefit from a drug designed to treat major depressive disorder, according to a study published this month in The Journal of Nuclear Medicine.
The C-DASB tracer targets a protein, 5-HTT, found in the part of a person’s brain that is responsible for emotional processing, called the amygdala. Escitalopram, a selective serotonin reuptake inhibitor, is indicated for people with depression, but it doesn’t work for all patients. Scanning a person’s brain to measure their 5-HTT level could help doctors determine if a patient will benefit from treatment with escitalopram, the researchers reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: PET imaging agent could help predict depression drug’s efficacy appeared first on MassDevice.